<DOC>
	<DOCNO>NCT01806649</DOCNO>
	<brief_summary>There need effective therapy patient esophageal squamous cell carcinoma develop disease progression first line therapy . Currently , standard second-line therapy disease . BKM-120 pan-PI3K inhibitor currently test clinical trial . In cellular model oral-esophageal carcinogenesis , show EGFR overexpression activate PI3/AKT pathway . Therfore , interest see efficacy safety BKM120 setting .</brief_summary>
	<brief_title>BKM120 Esophageal Squamous Cell Carcinoma After Failure First Line Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<criteria>Patient provide sign Informed Consent Form ( ICF ) obtain prior screening procedure . Age ≥ 18 year old Histologically confirm diagnosis esophageal squamous cell carcinoma available archival tissue evaluation study . Metastatic unresectable disease Received one prior chemotherapy biological therapy regimen unresectable metastatic disease More 30 day since prior chemotherapy , surgery , radiotherapy , investigational agent Measurable disease least 1 diameter CT scan MRI per RECIST 1.1 criterion No evidence brain metastasis ECOG ≤ 2 Patient adequate bone marrow organ function Absolute Neutrophil Count ( ANC ) ≥ 1.5 x 109/L Platelets ≥ 100 x 109/L Hemoglobin ≥ 9.0 g/dL INR ≤ 2 Potassium , calcium , magnesium within normal limit institution Serum Creatinine ≤ 1.5 x ULN Creatinine clearance &gt; 60 mL AST ALT 2.5 time ULN ( 5.0 time ULN liver metastasis ) Serum bilirubin within normal range ( ≤ 1.5 x ULN liver metastases present ; total bilirubin ≤ 3.0 x ULN direct bilirubin within normal range patient well document Gilbert Syndrome ) Fasting serum glucose &lt; 1.5 time ULN Patient receive previous treatment PI3K inhibitor Patient symptomatic CNS metastases Patients control asymptomatic CNS metastasis may participate trial . As , patient must complete prior treatment CNS metastases &gt; 28 day ( include radiotherapy and/or surgery ) prior enrollment study receive chronic corticosteroid therapy CNS metastasis . Patient concurrent malignancy malignancy within 5 year study enrollment , ( exception nonmelanoma skin cancer cervical carcinoma situ . Patient follow mood disorder judge Investigator Psychiatrist , meet cutoff score ≥ 10 PHQ9 cutoff ≥ 15 GAD7 mood scale , respectively , selects positive response ' 1 , 2 , 3 ' question number 9 regard potential suicidal thought ideation PHQ9 ( independent total score PHQ9 ) Medically documented history active major depressive episode , bipolar disorder ( I II ) , obsessivecompulsive disorder , schizophrenia , history suicidal attempt ideation , homicidal ideation ( immediate risk harm others ) ≥ CTCAE grade 3 anxiety Patient concurrently use approve investigational antineoplastic agent Patient major surgery within 28 day prior start study drug recover major side effect surgery Patient poorly control diabetes mellitus ( HbA1c &gt; 8 % ) Patient active cardiac disease include follow : LVEF &lt; 50 % QTc &gt; 480 msec screen ECG ( use QTcF formula ) Angina pectoris require use antianginal medication Ventricular arrhythmia except benign premature ventricular contraction Supraventricular nodal arrythmias require pacemaker control medication Conduction abnormality require pacemaker Valvular disease document compromise cardiac function Symptomatic pericarditis Patient history cardiac dysfunction include follow ; Myocardial infarction within last 6 month , document persistent elevated cardiac enzyme persistent regional wall abnormality assessment LVEF function History document congestive heart failure ( New York Heart Association functional classification IIIIV ) Documented cardiomyopathy Patient currently receive treatment QT prolong medication know risk induce Torsades de Pointes , treatment discontinue switched different medication prior start study drug Inability swallow , impaired gastrointestinal ( GI ) function , GI disease would significantly alter absorption study drug preclude use oral medication Patient concurrent severe and/or uncontrolled medical condition would , investigator 's judgment contraindicate participation clinical study ( e.g. , chronic pancreatitis , active chronic hepatitis etc . ) Patient currently treat drug know moderate strong inhibitor inducer isoenzyme CYP3A , treatment discontinue switched different medication prior start study drug .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>esophageal cancer</keyword>
	<keyword>second line therapy</keyword>
	<keyword>BKM120</keyword>
</DOC>